Balasubramanian indicated that IKS Health intends to expand its operations while sustaining margins in the early-to-mid 30% range and enhancing investments in artificial intelligence (AI) solutions.
For the complete interview, view the attached video
As of the end of the previous fiscal year, IKS Health’s net debt stood at approximately $26 million, and the company aims to return to similar debt levels by FY30, even with the acquisition funding.
She noted that IKS’s spending on artificial intelligence and R&D during the January-March 2026 quarter accounted for about 5% of revenue, and this is expected to rise in line with revenue growth moving forward. The company continues to gain from technology-driven operational leverage.
Also Read | India may experience another year of subdued earnings growth, states Emmer Capital CEO
Most of IKS’ contracts are based on outcomes, linking revenues to customer performance. “Risk and reward balance out. If patient volumes increase, our earnings rise accordingly,” Balasubramanian remarked.
The company further explained that customer rationalisation following the acquisition of AQuity Solutions was deliberate and may persist for several more quarters as it disengages from smaller accounts with limited growth potential.
The company, currently valued at a market capitalisation of ₹28,795.98 crore, has observed that its shares have remained stable over the past year.
Stay updated with the latest news from the stock market here
